Loading
Rare cancer patients are already tracked in registries. Offering randomisation inside the registry makes trials far cheaper and lets almost anyone take part.
Trials within cohorts, or registry-based randomised trials, use existing registry infrastructure for identification, consent, allocation and outcome capture, and have been used successfully in cardiology at a fraction of conventional trial cost. Rare cancers are ideal candidates because registries already exist, populations are dispersed, and conventional site-based trials cannot reach enough patients.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
Shares AACR Project GENIE, SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, ClinicalTrials.gov, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets.
Shares Basket, umbrella, and platform trials, Real-world evidence, Weak real-world evidence and registries, Rare and paediatric cancers without markets.
Shares AACR Project GENIE, SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries, Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Basket, umbrella, and platform trials, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares SEER (Surveillance, Epidemiology, and End Results), ClinicalTrials.gov, Real-world evidence, Weak real-world evidence and registries.